5 Oversold Biotech Stocks to Invest In Now

In this article, we will be taking a look at the 5 oversold biotech stocks to invest in now. If you wish to see the complete list, visit 8 Oversold Biotech Stocks to Invest In Now.

5. Cadrenal Therapeutics, Inc. (NASDAQ:CVKD)

Price Target Upside: 378.93%  

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) is among the oversold biotech stocks to invest in now.

TheFly reported on April 7 that H.C. Wainwright reduced its price target on CVKD from $32 to $13 while maintaining a Buy rating. The adjustment reflects updated assumptions around share count and financing requirements, along with the inclusion of CAD-1005 in the firm’s valuation model. The company also provided a recent update noting continued advancement of CAD-1005, including completion of its End-of-Phase 2 meeting with the U.S. Food and Drug Administration to define a potential Phase 3 registrational pathway.

This analyst activity follows Cadrenal Therapeutics, Inc. (NASDAQ:CVKD)’s March 31 announcement of its fourth-quarter and full-year 2025 financial results, which provided critical context for the updated price target, along with a corporate update on its CAD-1005 program for heparin-induced thrombocytopenia and its broader 12-LOX inhibitor platform. The company reported continued progress, including completion of an End-of-Phase 2 meeting with the U.S. FDA on March 26, 2026, to define a potential Phase 3 registrational pathway.

Phase 2 data showed fewer thrombotic events in patients receiving CAD-1005 compared to placebo, with more than a 25% absolute reduction observed on top of standard anticoagulation therapy. Research and development expenses were $0.7 million for the quarter, general and administrative expenses were $2.4 million, and net loss totaled $3.0 million. Cash and cash equivalents stood at $4.0 million, with financing options under evaluation.

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) is a late-stage biopharmaceutical company developing novel anticoagulant and anti-thrombotic therapies for life-threatening immune and cardiovascular conditions, including heparin-induced thrombocytopenia and chronic kidney disease-related clotting disorders.